Krystal Biotech
KRYS
23 hedge funds and large institutions have $47.6M invested in Krystal Biotech in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
35% more funds holding
Funds holding: 17 → 23 (+6)
34% more capital invested
Capital invested by funds: $35.5M → $47.6M (+$12.1M)
1.56% more ownership
Funds ownership: 23.18% → 24.75% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$10.5M |
| 2 |
SST
S Squared Technology
New York
|
+$904K |
| 3 |
Renaissance Technologies
New York
|
+$851K |
| 4 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$503K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$385K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.44M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$1.43M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
-$1.07M |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$1.02M |
| 5 |
Millennium Management
New York
|
-$383K |
KRYS Hedge Fund Activity: Q3 2018 in Review
23 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2018, worth a combined $47.6M — up 34% from $35.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new KRYS positions and 4 closed out — a net gain of 6 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Frazier Management, opening a new position worth an estimated $10.5M. The largest seller was Fidelity Investments, cutting an estimated $4.44M.
- 23 institutional investors held Krystal Biotech (KRYS) as of Q3 2018, up from 17 in Q2 2018.
- Funds reported $47.6M of Krystal Biotech stock for Q3 2018, up 34% quarter-over-quarter.
- 10 funds opened new Krystal Biotech positions in Q3 2018 and 4 closed out, a net change of +6 holders.
- The largest Krystal Biotech buyer in Q3 2018 was Frazier Management, an estimated $10.5M added.
- The largest Krystal Biotech seller in Q3 2018 was Fidelity Investments, an estimated $4.44M sold.
Based on aggregated 13F filings for Q3 2018.